%	O
%	O
TITLE	O

Rising	O
prevalence	B-Incidence_or_Prevalence
of	O
human	O
papillomavirus	O
-	O
related	O
oropharyngeal	O
cancer	O
in	O
Australia	B-Study_Location
over	O
the	O
last	O
2	O
decades	O
.	O

%	O
%	O
ABSTRACT	O

This	O
study	O
provides	O
Australian	B-Study_Location
data	O
on	O
the	O
characteristics	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
-	O
related	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
over	O
the	O
last	O
2	O
decades	O
.	O

The	O
HPV	O
status	O
of	O
515	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
oropharyngeal	I-Study_Cohort
SCC	I-Study_Cohort
diagnosed	O
between	O
1987	B-Study_Time
and	I-Study_Time
2010	I-Study_Time
was	O
determined	O
by	O
HPV	B-HPV_Lab_Technique
E6	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
targeted	I-HPV_Lab_Technique
multiplex	I-HPV_Lab_Technique
real	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
polymerase	I-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
assay	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
and	O
p16	B-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique
.	O

The	O
HPV	O
positivity	O
rate	O
increased	O
from	O
20	O
.	O
2	O
%	O
(	O
1987	O
-	O
1995	O
)	O
to	O
63	O
.	O
5	O
%	O
(	O
2006	O
-	O
2010	O
)	O
.	O

Among	O
HPV	O
-	O
positive	O
oropharyngeal	O
SCC	O
over	O
the	O
study	O
period	O
,	O
the	O
median	O
age	O
increased	O
from	O
55	O
.	O
4	O
years	O
to	O
59	O
.	O
8	O
years	O
(	O
pâ€‰=â€‰	O
.	O
004	O
)	O
and	O
there	O
was	O
a	O
trend	O
of	O
an	O
increasing	O
proportion	O
of	O
never	O
smokers	O
(	O
19	O
.	O
2	O
%	O
to	O
34	O
.	O
0	O
%	O
)	O
.	O

The	O
use	O
of	O
radiation	O
therapy	O
(	O
RT	O
)	O
in	O
patients	O
with	O
HPV	O
-	O
positive	O
oropharyngeal	O
cancer	O
increased	O
from	O
26	O
.	O
9	O
%	O
to	O
68	O
.	O
1	O
%	O
(	O
pâ€‰=â€‰	O
.	O
007	O
)	O
and	O
we	O
also	O
observed	O
a	O
trend	O
of	O
improved	O
outcomes	O
.	O
Our	O
data	O
show	O
a	O
rising	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
-	O
positive	O
oropharyngeal	O
SCC	O
in	O
Australia	B-Study_Location
over	O
the	O
last	O
2	O
decades	O
.	O

These	O
patients	O
with	O
HPV	O
-	O
positive	O
oropharyngeal	O
SCC	O
are	O
now	O
presenting	O
at	O
an	O
older	O
age	O
and	O
about	O
one	O
third	O
have	O
never	O
smoked	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Incidence	B-Incidence_or_Prevalence
of	O
oropharyngeal	O
cancer	O
in	O
Australia	B-Study_Location

Cancer	O
incidence	B-Incidence_or_Prevalence
data	O
were	O
obtained	O
from	O
the	O
National	O
Cancer	O
Statistics	O
Clearing	O
House	O
database	O
of	O
the	O
Austra	B-Study_Location
-	I-Study_Location
lian	I-Study_Location
Institute	O
of	O
Health	O
and	O
Welfare	O
(	O
AIHW	O
;	O
)	O
,	O
which	O
incorporates	O
data	O
from	O
the	O
8	O
Australian	O

TABLE	O
1	O
.	O

Patient	O
characteristics	O
by	O
human	O
papillomavirus	O
status	O
.	O

Abbreviation	O
:	O
HPV	O
,	O
human	O
papillomavirus	O
.	O

state	O
and	O
territory	O
cancer	O
registries	O
.	O

We	O
used	O
the	O
data	O
for	O
oropharyngeal	O
SCC	O
–	O
incorporating	O
the	O
base	O
of	O
tongue	O
(	O
C01	O
)	O
,	O
tonsil	O
(	O
C09	O
)	O
,	O
and	O
other	O
sites	O
within	O
the	O
oropharynx	O
(	O
C10	O
)	O
–	O
and	O
laryngeal	O
cancer	O
as	O
a	O
smoking	O
-	O
related	O
head	O
and	O
neck	O
cancer	O
for	O
comparison	O
.	O

Study	O
population	O

The	O
study	O
cohort	O
comprised	O
520	B-Study_Cohort
consecutive	I-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
primary	I-Study_Cohort
oropharyngeal	I-Study_Cohort
SCC	I-Study_Cohort
treated	O
with	O
curative	O
intent	O
at	O
10	O
hospitals	O
in	O
Australia	B-Study_Location
between	O
1987	B-Study_Time
and	I-Study_Time
2010	I-Study_Time
.	O

The	O
study	O
was	O
approved	O
by	O
Sydney	O
Local	O
Health	O
Service	O
Ethics	O
com	O
-	O
mittees	O
(	O
Protocol	O
x12–0141	O
)	O
.	O

The	O
oropharynx	O
is	O
defined	O
as	O
palatine	O
tonsil	O
(	O
tonsillar	O
fossa	O
,	O
tonsillar	O
pillar	O
)	O
,	O
base	O
of	O
tongue	O
,	O
soft	O
palate	O
,	O
and	O
posterior	O
walls	O
of	O
the	O
oropharynx	O
.	O

Patient	O
selection	O
was	O
based	O
on	O
the	O
availability	O
of	O
tumor	O
and	O
clinicopathological	O
data	O
.	O

The	O
HPV	O
status	O
of	O
the	O
oropharyn	O
-	O
geal	O
SCC	O
was	O
not	O
determined	O
at	O
the	O
time	O
of	O
diagnosis	O
and	O
therefore	O
treatment	O
decisions	O
were	O
not	O
based	O
on	O
HPV	O
status	O
.	O

Laboratory	O
studies	O

An	O
HPV	O
-	O
positive	O
tumor	O
was	O
defined	O
as	O
one	O
testing	O
posi	O
-	O
tive	O
for	O
both	O
HPV	O
DNA	O
and	O
p16	O
expression	O
to	O
ensure	O
virus	O
causality	O
.	O
12	O
Presence	O
and	O
type	O
of	O
HPV	O
DNA	O
were	O
deter	O
-	O

mined	O
on	O
two	O
to	O
six	O
4	O
to	O
5	O
mm	O
sections	O
of	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tumor	O
using	O
an	O
HPV	B-HPV_Lab_Technique
E6	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
based	I-HPV_Lab_Technique
multiplex	I-HPV_Lab_Technique
real	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
polymerase	I-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
assay	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	O
modified	O
from	O
Stanley	O
and	O
Szewczuk	O
.	O
13	O
This	O
assay	O
detects	O
and	O
identi	O
-	O
fies	O
21	O
HPV	O
types	O
(	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O

59	O
,	O
66	O
,	O
68	O
,	O
70	O
,	O
73	O
,	O
82	O
,	O
53	O
,	O
6	O
,	O
11	O
,	O
and	O
26	O
)	O
.	O

Stringent	O
precau	O
-	O
tions	O
were	O
taken	O
to	O
avoid	O
cross	O
-	O
contamination	O
and	O
water	O
blanks	O
placed	O
after	O
every	O
fifth	O
tube	O
to	O
detect	O
contamination	O
.	O

DNA	O
was	O
extracted	O
using	O
the	O
QIAmp	O
RNA	O
viral	O
mini	O
kit	O
(	O
Qiagen	O
,	O
Germany	O
)	O
.	O

Measured	O
amounts	O
of	O
equine	O
herpesvi	O
-	O
rus	O
were	O
used	O
to	O
monitor	O
DNA	O
extraction	O
efficiency	O
and	O
removal	O
of	O
PCR	B-HPV_Lab_Technique
inhibitors	O
.	O

The	O
presence	O
of	O
cancer	O
cells	O
was	O
confirmed	O
by	O
pathologist	O
C	O
.	O
S	O
.	O
L	O
.	O
in	O
hematoxylin	O
-	O
eosin	O
stained	O
sections	O
cut	O
after	O
those	O
for	O
HPV	O
analysis	O
.	O

Expression	B-HPV_Lab_Technique
of	I-HPV_Lab_Technique
p16	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
determined	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
semiquantitative	I-HPV_Lab_Technique
immunohisto	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
chemistry	I-HPV_Lab_Technique
using	O
an	O
autostainer	O
(	O
Dako	O
,	O
Australia	O
)	O
,	O
the	O
JC2	O
clone	O
(	O
Neomarkers	O
,	O
USA	O
)	O
(	O
1	O
/	O
200	O
)	O
and	O
the	O
EnVision	O
Flex	O
Dual	O
Link	O
horseradish	O
peroxidase	O
/	O
DAB	O
visualization	O
system	O
(	O
Dako	O
,	O
Australia	O
)	O
.	O

Staining	O
was	O
evaluated	O
by	O
2	O
investigators	O
,	O
including	O
a	O
pathologist	O
,	O
as	O
per	O
our	O
established	O
protocol	O
.	O
14	O

Statistical	O
analyses	O

Associations	O
between	O
HPV	O
status	O
and	O
clinicopathologi	O
-	O
cal	O
characteristics	O
were	O
assessed	O
using	O
a	O
2	O
-	O
sample	B-HPV_Sample_Type
t	O
test	O

for	O
the	O
continuous	O
variable	O
and	O
chi	O
-	O
square	O
tests	O
for	O
cate	O
-	O
gorical	O
variables	O
.	O

The	O
time	O
trend	O
in	O
the	O
proportion	O
of	O
oro	O
-	O
pharyngeal	O
cancers	O
testing	O
HPV	O
-	O
positive	O
was	O
analyzed	O
using	O
the	O
binary	O
test	O
for	O
trend	O
.	O

Times	O
to	O
locoregional	O
fail	O
-	O
ure	O
,	O
death	O
from	O
oropharyngeal	O
cancer	O
,	O
and	O
death	O
from	O
any	O
cause	O
were	O
calculated	O
from	O
the	O
date	O
of	O
diagnosis	O
.	O

Locoregional	O
recurrence	O
was	O
defined	O
as	O
clinical	O
,	O
radio	O
-	O
logical	O
,	O
and	O
/	O
or	O
pathological	O
evidence	O
of	O
recurrence	O
at	O
the	O
primary	O
site	O
or	O
in	O
the	O
regional	O
nodal	O
area	O
.	O

The	O
Kaplan–	O
Meier	O
method	O
was	O
used	O
to	O
construct	O
time	O
-	O
to	O
-	O
event	O
curves	O
.	O

